Over at Laszlo Biryini's shop, they've posted the 20 best and worst performing stocks in the Russell 2000 small-cap index for the first half of 2006. Nothing jumps off the page. Weight-loss firm Medifast (MED) almost quadrupled while biotech drugmaker Neurocrine Biosciences (NBIX) fell off a cliff, losing 83%.
It does make one wonder - is there a contrarian play here? Will the first half's losers run up for the rest of the year while winners take a tumble? At least based on the 2005 data, the trend is your friend and the contrarians will be punished. The 20 top performers of the first half of 2005 gained a modest 9% on average in the second half, with 10 showing losses. The 20 worst performers went on to lose another 16% on average with just six gainers.